5-MeO-DPAC

5-MeO-DPAC
Clinical data
Other names5-Methoxy-3-(dipropylamino)chroman; 5-Methoxy-3-(di-n-propylamino)chroman; 5-Methoxy-3,4-dihydro-N,N-dipropyl-2H-1-benzopyran-3-amine
Drug classSerotonin 5-HT1A receptor agonist
ATC code
  • None
Legal status
Legal status
  • Generally not controlled
Identifiers
  • 5-methoxy-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H25NO2
Molar mass263.381 g·mol−1
3D model (JSmol)
  • CCCN(CCC)C1CC2=C(C=CC=C2OC)OC1
  • InChI=1S/C16H25NO2/c1-4-9-17(10-5-2)13-11-14-15(18-3)7-6-8-16(14)19-12-13/h6-8,13H,4-5,9-12H2,1-3H3
  • Key:GOWYIQOIWRLZLO-UHFFFAOYSA-N

5-MeO-DPAC, also known as 5-methoxy-3-(dipropylamino)chroman, is a potent and highly selective serotonin 5-HT1A receptor full agonist related to 8-OH-DPAT. It is a derivative of 3-aminochroman, in which in the 5th position of the benzene ring there is a methoxy group, and in the 3rd position of dipropylamine.

The drug shows no affinity for other serotonin receptors or for the dopamine D2 receptor. It acts at very low concentrations, albeit with lower potency than 8-OH-DPAT, and unlike 8-OH-DPAT, does not bind to presynaptic serotonin 5-HT1A receptors in the striatum.

The mechanism of action of 5-MeO-DPAC is to reduce the synthesis and turnover of serotonin in the brain through selective activation of serotonin 5-HT1A autoreceptors, which is mediated through a negative feedback system without a direct effect on striatal binding sites.

Several analogues and positional isomers of 5-MeO-DPAC have also been described.

5-MeO-DPAC was first described in the scientific literature by 1987.

See also